Figure 2 is incorrect; panels C-F are missing. The figure legend is correct. The authors have provided a corrected version here.
A – Histopathology of 14 day K1492 and K1861 by H&E (first column 25×, second column 200×) and astrocytic markers S100b (200×) and GFAP (200×). 5×104 cells of K1492 (B) and K1861 (C) were intracranially implanted in C57Bl/6J mice and received 5×106 PFUs vMyx-FLuc (MYXV), UV-inactivated virus (DV), PBS, or no treatment (NT) on day 14. D – Luciferase measured (Total FLUX) from region-of-interest around the entire mouse skull following 5×106 PFUs vMyx-FLuc in K1492 (n = 8), K1861 (n = 10) or no tumour (n = 5). Error bars represent standard error. E – Viral recovery from K1492 (n = 4) and K1861 (n = 4) tumours following intracranial treatment with vMyx-FLuc. Input virus represents mice where virus was recovered 1 hour post-injection. Error bars represent standard error. F – Immunohistochemical staining for early MYXV protein MT-7e in 14 day K1492 at 1, 3 and 7 days post-treatment (Top row 25×; Bottom row 100×).
- 1. Zemp FJ, McKenzie BA, Lun X, Maxwell L, Reilly KM, et al. (2013) Resistance to Oncolytic Myxoma Virus Therapy in Nf1−/−/Trp53−/− Syngeneic Mouse Glioma Models Is Independent of Anti-Viral Type-I Interferon. PLoS ONE 8(6): e65801 doi:https://doi.org/10.1371/journal.pone.0065801.
Citation: The PLOS ONE Staff (2014) Correction: Resistance to Oncolytic Myxoma Virus Therapy in Nf1−/−/Trp53−/− Syngeneic Mouse Glioma Models Is Independent of Anti-Viral Type-I Interferon. PLoS ONE 9(6): e101827. https://doi.org/10.1371/journal.pone.0101827
Published: June 26, 2014
Copyright: © 2014 The PLOS ONE Staff. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.